1. Home /
    2. Altai Protocol Library /
  2. New Indication: Dostarlimab for dMMR solid cancers

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Dostarlimab for dMMR solid cancers

New Indication: Dostarlimab for dMMR solid cancers
Study:
  • Cohort F of phase I GARNET trial
  • Progressed following systemic therapy and dMMR by IHC (mostly GI tract origin)
  • Dostarlimab 500 mg q21 x 4 => 1000 mg q42 (N=106)
Efficacy:
  • ORR: 38.7% [29.4% – 48.6%]
  • Probability of maintaining response @ 12 mos: 91.0%
  • 56% of responders with ccRCC had DoR over one year
Safety:
  • Grade >= 3 AEs reported in 8.3% of pts. Most common was increased lipase (1.4%)

J Clin Oncol 2021;39: suppl 9.

Andre T, et al. Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study

https://doi.org/10.1200/JCO.2021.39.3_suppl.9

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More